BioMarin Jumps as Drug Hits Goals: San Francisco Mover

BioMarin Pharmaceutical Inc. (BMRN), a maker of drugs for rare diseases, rose to its highest value ever after its medicine for an enzyme deficiency disease met goals in a study, prompting plans to seek regulatory approval next year.

BioMarin jumped 31 percent to $49.07 in New York, its highest price since the shares began trading in July 1999, after releasing results today from the late-stage trial of its GALNS medicine. The Novato, California-based company has risen 43 percent this year.

The disease, mucopolysaccharidosis IVA, is also known as Morquio A syndrome, and it affects an estimated 2,500 to 3,000 patients worldwide, according to BioMarin. It can lead to short stature and problems in the joints, which may inhibit mobility. BioMarin’s drug, a replacement enzyme, helped patients walk 22.5 meters (73.8 feet) farther in six minutes than placebo, the primary goal of the study, the company said in a statement.

“We fully expect GALNS to be approved on the basis of this study,” Cory Kasimov, an analyst with JPMorgan Chase & Co. (JPM) in New York, wrote in a note to clients. “We view the result as clearly positive for BioMarin and see it as a best-case outcome.”

The drug was generally well-tolerated in the trial, the third and final phase generally required for regulatory approval. GALNS also helped with secondary goals of the study, including improvement in a three-minute stair climb and reduction in urinary keratan sulfate levels, a measure of the presence of the enzyme.

“The GALNS clinical program is currently the highest development priority at BioMarin, and this positive Phase 3 study serves as a potentially transformative milestone for the company,” BioMarin Chief Executive Jean-Jacques Bienaimé said in the statement.

To contact the reporter on this story: Meg Tirrell in New York at

To contact the editor responsible for this story: Reg Gale at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.